Case Studies in PDXs

Service Pages

Questions?

Home 5 Service 5 Case Studies in PDXs

Mouse Clinical Trial in PDXs

Objective: to evaluate drug efficacy across 17 colorectal PDXs

Pre-defined Clinical Endpoints

  • Tumor Progression
    • A tumor volume change >73% by the end of treatement
  • Tumor Stasis
    • A tumor volume change between -66% and 73% by the end of treatment
  • Tumor Regression
    • A tumor volume change -66% by the end of treatment
  • Complete Tumor Regression
    • Non-palpable tumors

%TV = ((TV end of treatment – TV start of treatment)/TV start of treatment) x 100

 

Efficacy and Biomarker Assessment in PDXs

Cancer Res; 2017, 77(24);6999-7013

  • Efficacy of FGFR4 inhibitor in 30 HCC PDX models, and FGF19 IHC were all performed at ChemPartner
  • FGF19 expression level correlates well with drug efficacy, implicating that FGF19 overexpression is a predictive biomarker for FGFRi response.

Headquarters

1F & 3F, Block A
2829 JinKe Road
Zhangjiang Hi-Tech Park
PuDong New Area
Shanghai China, 201203

w

Contact Us

China: +86 21 5132 0088
US: +1 650 419 9974
Europe: +45 4586 9000
Japan: +81 03 5403 6975

contact@chempartner.com